Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**TXN10128 + paclitaxel** is an investigational combination therapy being studied in adults with locally advanced or metastatic solid tumors that have relapsed or are refractory to standard treatment. TXN10128 is a small molecule inhibitor of ENPP1 (Ectonucleotide pyrophosphatase/phosphodiesterase family member 1), designed to disrupt ENPP1-mediated pathways involved in tumor progression. Paclitaxel is a well-established microtubule-stabilizing chemotherapeutic agent that inhibits cell division, approved for multiple cancer indications. The combination is delivered as oral TXN10128 and intravenous paclitaxel, with a Phase 1 clinical trial currently recruiting to evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor activity in solid tumors, including specific arms for breast cancer patients[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TXN10128 + paclitaxel.